Investors

Webcast ImageWebcast
Depomed at the Piper Jaffray 26th Annual Healthcare Conference (Replay)
12/02/14 at 8:00 a.m. ET

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market four FDA-approved products, Gralise®, Cambia®, Zipsor®, and Lazanda®. We actively seek to expand our product portfolio through in-licensing, acquiring or obtaining co-promotion rights to commercially available products or late-stage product candidates that could be marketed and sold effectively with our existing products through our sales and marketing capability. In addition, Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. We have licensed Acuform technology to six pharmaceutical partners and the technology is currently being used in four marketed drugs, including Gralise.

The following are abbreviated descriptions of our products:

Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, Cambia®(diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,  Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults, and Lazanda® (fentanyl) nasal spray CII for the  management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain.  See Important Safety Information for Gralise and the black box warnings for CambiaZipsor, and Lazanda.

Recent News> MORE
DateTitle 
11/20/14Depomed To Present At Piper Jaffray 26th Annual Healthcare ConferencePrinter Friendly Version
11/12/14Depomed To Present At Stifel 2014 Healthcare ConferencePrinter Friendly Version
11/05/14Depomed Reports Third Quarter 2014 Financial ResultsPrinter Friendly Version
Upcoming and Recent Events> MORE
DateTitle
12/02/14
8:00 a.m. ET
Depomed at the Piper Jaffray 26th Annual Healthcare Conference
LocationNew York City
11/18/14
3:35 p.m. ET
Depomed at the Stifel 2014 Healthcare Conference
LocationNew York City
11/05/14
4:30 p.m. ET
Q3 2014 Depomed Earnings Conference Call
Supporting Materials
Download Event Supporting Material Depomed Q3 2014 Earnings Conference Transcript

DEPO (Common Stock)

Exchange
NASDAQ CM
Price
$16.14
Change (%)
 - 0.1 (0.62%)
Volume
286,359
Market Cap
$948,063,600

Data as of 12/22/14 2:04 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.